The Schall Law Firm announced an investigation into Certara, Inc. (NASDAQ: CERT) for potential securities law violations following the company's May 11, 2026 Q1 earnings report. Certara disclosed declining services revenues and bookings, attributing the weakness to softer performance from Tier 1 customers in MIDD services. The stock fell 19% on the announcement, prompting the law firm to seek shareholders who suffered losses.

Law firm Kirby McInerney LLP is investigating Certara, Inc. for potential securities law violations following the company's Q1 2026 earnings report, which revealed a 4% decline in services revenue and 14% decline in services bookings, along with softer Tier 1 customer performance and exit from the regulatory business. The stock price fell 19% on the news.

The biosimulation market is experiencing robust growth, projected to expand from USD 4.7 billion in 2025 to USD 20 billion by 2034 at a CAGR of ~17%. Growth is driven by increasing adoption of model-informed drug development (MIDD), rising complexity of modern therapeutics, regulatory support from FDA and EMA, and the shift toward virtual clinical trials and precision medicine. North America leads the market with 44.24% share, while Asia-Pacific emerges as a major growth contributor.

The clinical trial software market is expected to grow from $1.32 billion in 2025 to $2.53 billion by 2030, with a CAGR of 13.8%. Growth drivers include increased digitization, adoption of AI and cloud-based solutions, virtual and decentralized trials, and enhanced data security focus. Major players are innovating with unified trial solutions and strategic acquisitions to strengthen their market positions.

Certara announced the sale of its Regulatory and Medical Writing business to Veristat for up to $135 million. The divestiture is expected to close in Q2 2026 and will allow the company to focus on its Model-Informed Drug Development platform. Analysts view this as strategically positive timing, with William Blair noting it removes an overhang and provides capital for reinvestment in core biosimulation platforms.

Kopion Asset Management purchased 327,064 additional shares of Certara (worth ~$3.37 million) during Q4, despite the stock falling 23% post-earnings. The fund views the sharp decline as a buying opportunity, noting that Certara's underlying business remains solid with 10% revenue growth and improved profitability, making it an attractive entry point for disciplined investors.

Certara announced Jon Resnick will become CEO on January 1, 2026, succeeding William Feehery. Resnick brings over 20 years of experience from IQVIA and previously worked in healthcare policy, bringing leadership expertise in health sciences and business operations.

The global In Silico Clinical Trials Market is projected to grow from $3.42 billion in 2023 to $6.68 billion by 2032, driven by AI-based modeling, regulatory support, and accelerated drug development strategies.

Certara launches AI-powered Quantitative Systems Pharmacology (QSP) platform called Certara IQ, highlighting the company's technological innovation in drug development. The company also celebrates its scientific achievements with 200 published papers and 11 scientists recognized among top cited researchers.

Certara, a biosimulation technology company, will release its third quarter 2025 financial results on November 6th, hosting a conference call at 5:00 PM ET for investors.

Certara introduces Pinnacle 21 Enterprise Plus, a software solution that helps clinical and statistical programmers efficiently create and manage data specifications for regulatory submissions, promising a 50% reduction in time spent drafting mapping specifications.

The global biosimulation market is expected to grow from USD 3.97 billion in 2024 to USD 18.97 billion by 2034, with a CAGR of 16.9%. North America currently dominates the market, driven by technological advancements and increasing research in drug development and discovery.